Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. |
Contact Details
Address: 117 Kendrick Street, Suite 450 Needham, Massachusetts 02494 United States | |
| Phone | 617-916-5445 |
| Website | candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. | Founder and Director |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical and Development Officer |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Charles Schoch | Interim Chief Financial Officer, Vice President of Finance and Corporate Controller |
| Ileen B. Winick | Chief People Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 8-K | Current Report |
| May 30, 2024 | ARS | Filing |
| May 30, 2024 | DEF 14A | Other definitive proxy statements |
| May 30, 2024 | 8-K | Current Report |
| May 24, 2024 | 424B5 | Filing |
| May 23, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 10-K/A | [Amend] Annual report |